PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35231767-0	2022	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.	regorafenib	71-82	angiopoietin 2	Homo sapiens	20-34	
35231767-6	2022	RESULTS: In the "regorafenib exploratory cohort", the early (d15) increase of Angiopoietin-2 (Ang-2) was associated with longer progression-free survival (HR:0.57 (95%CI:0.38-0.88), P = 0.004) and a trend towards longer OS (HR:0.74 (95%CI:0.48-1.14), P = 0.165), than the early decrease.	regorafenib	17-28	angiopoietin 2	Homo sapiens	78-92	
35231767-6	2022	RESULTS: In the "regorafenib exploratory cohort", the early (d15) increase of Angiopoietin-2 (Ang-2) was associated with longer progression-free survival (HR:0.57 (95%CI:0.38-0.88), P = 0.004) and a trend towards longer OS (HR:0.74 (95%CI:0.48-1.14), P = 0.165), than the early decrease.	regorafenib	17-28	angiopoietin 2	Homo sapiens	94-99	
35231767-10	2022	CONCLUSIONS: The early modulation of circulating Ang-2 predicts the efficacy of regorafenib.	regorafenib	80-91	angiopoietin 2	Homo sapiens	49-54	
30802985-0	2019	Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma.	regorafenib	34-45	angiopoietin 2	Homo sapiens	0-14